Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG0259 plus methotrexate in active rheumatoid arthritis with inadequate methotrexate response
NL-OMON34069Phase 2Withdrawn
- Sponsor
- Galapagos NV
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GLPG-0259 in rheumatoid arthritis (RA) (4 arms), sponsored by Galapagos NV. Primary endpoint: ACR20 response rate at Week 12. Planned start Jun 2010; status: withdrawn.
02
Drugs
GLPG-0259
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34069.